FOR Designation Could Limit U.S. Investors in Anteris’ Latest Offer

Updated Capital Raising Timeline

Anteris Technologies Global Corp., a leader in structural heart medical devices, has announced a revision to the timetable for the Australian component of its ongoing capital raising. The settlement date for the offer has been pushed back by one day to November 4, 2025, with the allotment and commencement of trading for new CHESS Depositary Interests (CDIs) and CDI Warrants now scheduled for November 5, 2025. This adjustment follows the initial announcement made on October 28, 2025.

Implications of the FOR Designation

Alongside the timetable update, Anteris reiterated that the Foreign Ownership Restriction (FOR) designation will apply to all new CDIs. This regulatory measure restricts U.S. persons, as defined under U.S. securities law, from acquiring these securities. The FOR designation aims to ensure compliance with cross-border investment rules but may influence the liquidity and investor base for the new shares on the ASX.

Company and Product Context

Founded in Australia with a significant presence in the United States and Europe, Anteris Technologies is focused on innovative solutions for structural heart disease. Its flagship product, the DurAVR Transcatheter Heart Valve, is a biomimetic device designed to replicate the function of a healthy aortic valve. The valve incorporates Anteris’ patented ADAPT tissue technology, which has FDA clearance and a decade-long clinical track record in over 55,000 patients worldwide.

Market and Regulatory Considerations

The updated timetable remains indicative and subject to change at the company’s discretion, pending ASX approval. Investors should note that such adjustments are not uncommon in capital raising processes but can affect trading strategies and market sentiment. The FOR designation, while regulatory in nature, introduces an additional layer of complexity for U.S.-based investors and may impact demand dynamics for the new securities.

Looking Ahead

As Anteris progresses with this capital raising, market participants will be watching closely for final ASX approvals and any further timetable changes. The company’s ability to successfully complete this raise will be critical in supporting its ongoing development and commercialization efforts in the competitive structural heart device sector.